B
Barbara Metch
Researcher at Fred Hutchinson Cancer Research Center
Publications - 42
Citations - 2519
Barbara Metch is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: HIV vaccine & Vaccination. The author has an hindex of 22, co-authored 42 publications receiving 2387 citations. Previous affiliations of Barbara Metch include HIV Vaccine Trials Network.
Papers
More filters
Journal ArticleDOI
Quality of Life End Points in Cancer Clinical Trials: Review and Recommendations
Carol M. Moinpour,Polly Feigl,Barbara Metch,Katherine A. Hayden,Frank L. Meyskens,John Crowley +5 more
TL;DR: Policy issues that influenced the development of policies for inclusion of quality of life end points in certain Southwest Oncology Group clinical trials are reviewed and specific questionnaires with psychometric properties are recommended.
Journal ArticleDOI
Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Glenda E. Gray,Mary Allen,Zoe Moodie,Gavin J. Churchyard,Linda-Gail Bekker,Maphoshane Nchabeleng,Koleka Mlisana,Barbara Metch,Guy de Bruyn,Mary H. Latka,Surita Roux,Matsontso Mathebula,Nivashnee Naicker,Constance. Ducar,Donald K. Carter,Adrian Puren,Niles. Eaton,M. Juliana McElrath,Michael N. Robertson,Lawrence Corey,James G. Kublin +20 more
TL;DR: The MRKAd5 HIV- 1 vaccine did not prevent HIV-1 infection or lower viral-load setpoint; however, stopping the trial early probably compromised the ability to draw conclusions.
Journal ArticleDOI
Primary Tubal Infertility in Relation to the Use of an Intrauterine Device
Janet R. Daling,Noel S. Weiss,Barbara Metch,Wong Ho Chow,Richard M. Soderstrom,Donald E. Moore,Leon R. Spadoni,Bruce V. Stadel +7 more
TL;DR: It is concluded that use of the Dalkon Shield (and possibly of plastic IUDs other than those that contain copper) can lead to infertility in nulligravid women.
Journal ArticleDOI
Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation.
TL;DR: In multivariate analysis, refusal was higher among African Americans and lower in persons >40 years of age, those attending college, and those with ≥5 partners in the prior 6 months, and in multivariable logistic models, which can minimize potential social harms and to mobilize diverse communities to enroll in trials.
Journal ArticleDOI
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery
Spyros A. Kalams,Scott D. Parker,Marnie Elizaga,Barbara Metch,Srilatha Edupuganti,John Hural,Stephen C. De Rosa,Donald K. Carter,Kyle Rybczyk,Ian Frank,Jonathan D. Fuchs,Beryl A. Koblin,Denny H. Kim,Patrice Joseph,Michael C. Keefer,Lindsey R. Baden,John H. Eldridge,Jean D. Boyer,Adam Sherwat,Massimo Cardinali,Mary Allen,Michael Pensiero,Christopher C Butler,Amir S. Khan,Jian Yan,Niranjan Y. Sardesai,James G. Kublin,David B. Weiner +27 more
TL;DR: This study illustrates the power of combined DNA approaches to generate impressive immune responses in humans by using electroporation after PV administration to provide immunogenicity superior to that observed in the trial without Electroporation, despite fewer vaccinations.